Alnylam Pharmaceuticals, Inc. (ALNY)

Market Cap	31.76B
Revenue (ttm)	2.09B
Net Income (ttm)	-332.26M
Shares Out	128.98M
EPS (ttm)	-2.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	512,976
Open	251.28
Previous Close	249.16
Day's Range	245.69 - 253.50
52-Week Range	141.98 - 304.39
Beta	0.34
Analysts	Buy
Price Target	299.09 (+21.45%)
Earnings Date	Feb 13, 2025

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2004
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: ALNY
• Website: https://www.alnylam.com

Financial Performance

In 2023, Alnylam Pharmaceuticals's revenue was $1.83 billion, an increase of 76.23% compared to the previous year's $1.04 billion. Losses were -$440.24 million, -61.08% less than in 2022.

Analyst Forecast

According to 24 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $299.09, which is an increase of 21.45% from the latest price.

Price Target

$299.09

(21.45% upside)

Analyst Consensus: Buy